CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Botox Cosmetic Injectable Product +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04755595
NCT04755595Phase 2Completed

Combination Facial Aesthetic Treatment in Millennials

State University of New York - Downstate Medical Center·interventional·Posted Feb 16, 2021·Updated Jan 14, 2025

In Brief

A Phase 2 clinical trial evaluating Botox Cosmetic Injectable Product, Juvéderm Voluma XC, and 1 other intervention for Dermatological Non-Disease. Completed, enrolled 20 participants across 1 site.

Detailed Summary

With 63% of consumers willing to consider investing in facial aesthetics and 73% of consumers worldwide expecting to invest in aesthetic treatments in the upcoming year, it is imperative to explore patient satisfaction and psychosocial impact of a multimodal aesthetic treatment in a millennial cohort. The investigators hypothesize that a combination approach to facial aesthetic treatment in a millennial cohort will result in increased patient-reported satisfaction in multiple areas, including perception of aging concerns and quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAllergan Sales, LLC

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 16, 2021
Enrollment StartMar 9, 2021
Primary CompletionMay 19, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.4 years ago

Interventions

Botox Cosmetic Injectable Productdrug

Acetylcholine release inhibitor and a neuromuscular blocking agent

Juvéderm Voluma XCdevice

Gel implants consisting of cross-linked hyaluronic acid

Juvéderm Volbella XCdevice

Gel implants consisting of cross-linked hyaluronic acid